Vallon Pharmaceuticals, Inc. (NASDAQ:VLON – Get Rating) was the target of a significant increase in short interest in the month of July. As of July 15th, there was short interest totalling 140,300 shares, an increase of 186.9% from the June 30th total of 48,900 shares. Approximately 2.9% of the company’s shares are sold short. Based on an average daily volume of 3,340,000 shares, the short-interest ratio is presently 0.0 days.
Vallon Pharmaceuticals Trading Down 6.9 %
NASDAQ:VLON opened at $0.40 on Friday. Vallon Pharmaceuticals has a 1-year low of $0.34 and a 1-year high of $3.45. The firm has a market capitalization of $2.74 million, a price-to-earnings ratio of -0.29 and a beta of -0.86. The business’s 50-day moving average price is $0.54 and its two-hundred day moving average price is $2.73.
Vallon Pharmaceuticals (NASDAQ:VLON – Get Rating) last announced its quarterly earnings results on Monday, May 9th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.17). Sell-side analysts predict that Vallon Pharmaceuticals will post -0.99 earnings per share for the current year.
Hedge Funds Weigh In On Vallon Pharmaceuticals
About Vallon Pharmaceuticals
Vallon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy.
- Get a free copy of the StockNews.com research report on Vallon Pharmaceuticals (VLON)
- Can International Business Machines Recover After Its Sell-Off?
- Wingstop And Hershey Are Two Food Stocks Overcoming Inflation
- Ford Stock Rallies As EV Strategy Takes Center Stage
- Should High Yield Altria Be In Your Portfolio?
- Is Keurig-Dr. Pepper A Value Worth Buying?
Receive News & Ratings for Vallon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vallon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.